Trexquant Investment LP Makes New $3.10 Million Investment in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Trexquant Investment LP acquired a new position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDXFree Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 143,514 shares of the company’s stock, valued at approximately $3,101,000.

Other large investors have also added to or reduced their stakes in the company. Teacher Retirement System of Texas grew its position in Syndax Pharmaceuticals by 5.1% in the 3rd quarter. Teacher Retirement System of Texas now owns 15,619 shares of the company’s stock valued at $227,000 after acquiring an additional 757 shares during the last quarter. Arizona State Retirement System increased its holdings in shares of Syndax Pharmaceuticals by 5.3% in the fourth quarter. Arizona State Retirement System now owns 16,511 shares of the company’s stock valued at $357,000 after purchasing an additional 835 shares during the period. New York State Common Retirement Fund increased its holdings in shares of Syndax Pharmaceuticals by 3.6% in the third quarter. New York State Common Retirement Fund now owns 30,825 shares of the company’s stock valued at $448,000 after purchasing an additional 1,080 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Syndax Pharmaceuticals by 9.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,126 shares of the company’s stock valued at $305,000 after purchasing an additional 1,162 shares during the period. Finally, CWM LLC grew its holdings in Syndax Pharmaceuticals by 415.3% during the fourth quarter. CWM LLC now owns 1,685 shares of the company’s stock worth $36,000 after acquiring an additional 1,358 shares during the period.

Analysts Set New Price Targets

Several analysts recently commented on SNDX shares. Citigroup dropped their target price on Syndax Pharmaceuticals from $32.00 to $30.00 and set a “buy” rating on the stock in a report on Thursday, May 9th. HC Wainwright reaffirmed a “buy” rating and issued a $41.00 price target on shares of Syndax Pharmaceuticals in a research note on Thursday, May 9th. Stifel Nicolaus upped their target price on Syndax Pharmaceuticals from $39.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, May 9th. Scotiabank cut Syndax Pharmaceuticals from a “sector outperform” rating to a “sector perform” rating and dropped their target price for the company from $36.00 to $23.00 in a report on Wednesday, January 31st. Finally, JPMorgan Chase & Co. restated an “overweight” rating and issued a $34.00 target price on shares of Syndax Pharmaceuticals in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, Syndax Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $34.42.

Check Out Our Latest Stock Analysis on Syndax Pharmaceuticals

Syndax Pharmaceuticals Trading Up 0.8 %

SNDX traded up $0.17 during mid-day trading on Friday, hitting $20.28. 821,743 shares of the stock were exchanged, compared to its average volume of 950,271. The firm’s fifty day moving average is $21.85 and its two-hundred day moving average is $20.76. Syndax Pharmaceuticals, Inc. has a 1-year low of $11.22 and a 1-year high of $25.34. The company has a market cap of $1.72 billion, a PE ratio of -6.30 and a beta of 1.01.

Syndax Pharmaceuticals (NASDAQ:SNDXGet Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.11. During the same period last year, the business posted ($0.59) earnings per share. As a group, research analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.58 earnings per share for the current year.

Syndax Pharmaceuticals Profile

(Free Report)

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).

Featured Articles

Want to see what other hedge funds are holding SNDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syndax Pharmaceuticals, Inc. (NASDAQ:SNDXFree Report).

Institutional Ownership by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.